WHO Updates Essential Medicines List for Hemophilia and VWD: Louise Bannon Applauds Global Hematology Community’s Achievement
Louise Bannon, Director of Membership, Marketing and External Relations of ISTH, shared a post on LinkedIn:
”In today’s news!
WHO Updates Essential Medicines List to Improve Care for People with Bleeding Disorders
The World Health Organization (WHO) has updated its Essential Medicines List (EML) and Essential Medicines List for Children (EMLc) to better align with international clinical guidelines for the management of hemophilia and von Willebrand Disease (VWD).
These revisions will help ensure that decision makers worldwide are guided by the latest evidence when selecting and financing essential medicines, improving access to safer and more effective therapies for people with bleeding disorders (PWBDs).
Key updates include:
- New medicines added: Bi-specific monoclonal antibody emicizumab; recombinant FVIII and FIX clotting factor concentrates (CFCs)
- Existing medicines upgraded: Plasma-derived FVIII and FIX CFCs and desmopressin moved from the complementary to the core list
- Medicines removed: Pathogen-reduced and non-pathogen-reduced cryoprecipitate and Factor IX Complex (PCC)
Congratulations to the global hematology community for advocating strongly to achieve these revisions, ensuring that people with bleeding disorders have access to modern, safe, and effective therapies.
ISTH applauds the leadership of the World Federation of Hemophilia (WFH) and its partners for mobilizing this milestone effort and supporting equitable treatment access worldwide.”
Find the latest news in the World of Bleeding Disorders featured in Hemostasis Today.
-
Oct 27, 2025, 12:12Maria Roussakis: It is an Honour to Be a Part of the ISBT Young Professionals Council
-
Oct 27, 2025, 05:47Ahmed Koriesh on The Novel Approach in Use of Tenecteplase
-
Oct 27, 2025, 04:42Louise Breslin: Exciting Results in The CRYPTICS Trial
-
Oct 26, 2025, 16:55ECTH 2025: 3 Unforgettable Days of Science and Shared Purpose
-
Oct 26, 2025, 16:35Ahmed Koriesh on Thrombolysis in Stroke Patients on DOACs
-
Oct 27, 2025, 13:00Hossam El Benawi Shares Multi Site LVT Study from Mayo Clinic
-
Oct 27, 2025, 08:01Acquired Hemophilia A (AHA) is Rare and Often Missed - RPTH Journal
-
Oct 27, 2025, 05:00Wolfgang Miesbach on WFH Guidelines Covering FDA/EMA-Approved AAV Gene Therapy for Hemophilia
-
Oct 26, 2025, 15:04Nita Radhakrishnan and Colleagues on Inherited Haematological Conditions
-
Oct 26, 2025, 14:55Anirban Sen Gupta on Biosynthetic Blood Surrogates Current State-of-Art
-
Oct 25, 2025, 07:42Adithya Hande: India’s Silent Killer and a Scientific Breakthrough
-
Oct 23, 2025, 09:57Arun V. J: Artificial Blood Is Closer Than You Think
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 27, 2025, 13:18Stroke Foundation Welcomes Jacqui McCallum as the New Executive Director
-
Oct 27, 2025, 12:54Guillermo Lahera Forteza on Stroke and Mental Health
-
Oct 27, 2025, 12:37Joshua Ngimbwa Recognised as the Best Male Junior Investigator Awardee at the Tanzania Health Summit
-
Oct 27, 2025, 08:00Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation
-
Oct 27, 2025, 06:30Andres Ricaurte Fajardo on CVT Experience from a Latin American Cohort